Advanced Cell Technology’s European Clinical Trial Advances to First Patient Treatment with Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
10/22/2012 9:36:42 AM
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its European clinical trial for Stargardt’s Macular Dystrophy (SMD). The patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with 50,000 cells in the three patients comprising the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully.
comments powered by